摘要
目的:研究地黄导痰汤制剂对血管性痴呆患者血清NO、ET-1、SOD及MDA的影响。方法:将62例本病患者随机分为两组各31例。在基础治疗的基础上治疗组予地黄导痰汤制剂口服,对照组予尼莫地平片口服,疗程为12周。结果:两组患者治疗后血清NO均较治疗前增加(P<0.05或P<0.01),ET-1均较治疗前降低(P<0.05或P<0.01);治疗组治疗后血清NO高于对照组(P<0.01),ET-1低于对照组(P<0.01)。治疗组患者治疗后血清SOD较治疗前增加(P<0.05),血清MDA含量较治疗前降低(P<0.05);治疗组治疗后血清SOD高于对照组(P<0.01),血清MDA含量低于对照组(P<0.01)。结论:地黄导痰汤制剂可促进血管性痴呆患者内皮细胞释放血清NO,减少血清ET-1释放;增加血清SOD含量,减少血清MDA含量。
Objective： To investigate the effect of Dihuang Daotan preparation（地黄导痰汤制剂,DHDTP） on patients with vascular dementia.Methods： The 62 patients were randomly divided into two groups,31 cases in each.On the basis of treatment,the treatment group was given DHDTP,the control group was give nimodipine tablets,both treat for twelve weeks.Results： After treatment,the serum NO of two groups were significantly increased（P〈0.05 or P〈0.01）,ET-1 were decreased（P〈0.05 or P〈0.01）.After treatment,the serum NO of treatment group was higher than that of control group（P〈0.01）,ET-1 was lower than the control group（P〈0.01）.After treatment,serum SOD in the treatment group increased（P〈0.05）,serum MDA content decreased（P〈0.05）; after treatment,serum SOD of treatment group was higher than the control group（P〈0.01）,and serum MDA levels were lower than the control group（P〈0.01）.Conclusion： DHDTP can promote the release of serum NO,decrease the release of serum ET-1,increase the content of serum SOD and decrease the content of serum MDA in patients with vascular dementia.
出处
《中医药导报》
2017年第20期87-89,共3页
Guiding Journal of Traditional Chinese Medicine and Pharmacy
基金
北京中医药大学东直门医院交流合作项目(2012YLJT-012)
